Delzicol

— THERAPEUTIC CATEGORIES —
  • Colorectal disorders
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Delzicol Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Mesalamine 400mg; del-rel caps; contains iron 2.7mg/tab.

    Pharmacological Class

    Salicylate.

    How Supplied

    Caps—180

    Manufacturer

    AbbVie

    Generic Availability

    YES

    Mechanism of Action

    The mechanism of action of mesalamine is not fully understood, but appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (eg, prostanoids), and through the lipoxygenase pathways (eg, leukotrienes and hydroxyeicosatetraenoic acids), is increased in patients with ulcerative colitis, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.

    Delzicol Indications

    Indications

    Mildly to moderately active ulcerative colitis (UC) in patients ≥5 years of age. Maintenance of remission of UC in adults.

    Delzicol Dosage and Administration

    Adult

    Swallow caps whole; if unable to swallow, may open and swallow contents (four 100mg tabs). Treatment: 800mg 3 times daily for 6 weeks. Maintenance: 1.6g/day in 2–4 divided doses. Do not substitute two Delzicol 400mg caps with one mesalamine 800mg del-rel tab.

    Children

    <5yrs: not established. Give twice daily dosing for 6 weeks. ≥5yrs (17–32kg): 36–71mg/kg/day, up to max 1.2g/day (800mg in the AM + 400mg in the afternoon); (33–53kg): 37–61mg/kg/day, up to max 2g/day (1200mg in the AM + 800mg in the afternoon); (54–90kg): 27–44mg/kg/day, up to max 2.4g/day (1200mg in the AM + 1200mg in the afternoon).

    Delzicol Contraindications

    Not Applicable

    Delzicol Boxed Warnings

    Not Applicable

    Delzicol Warnings/Precautions

    Warnings/Precautions

    Sulfasalazine allergy. Discontinue if acute intolerance syndrome is suspected. Discontinue at the 1st signs/symptoms of severe cutaneous adverse reactions. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Consider iron content of Delzicol in those taking iron supplementation or at risk of iron overload. Renal or hepatic impairment. History of renal disease. Assess renal function prior to and periodically during therapy. Discontinue if renal function deteriorates while on therapy. Elderly (monitor CBCs, platelets). Pregnancy. Nursing mothers: monitor infants.

    Delzicol Pharmacokinetics

    Absorption

    Approximately 28% of mesalamine in mesalamine delayed-release formulation is absorbed after oral ingestion.

    Metabolism

    Hepatic.

    Elimination

    Renal, fecal (minor). Half-life: ~25 hours (range: 1.5–296 hours).

    Delzicol Interactions

    Interactions

    Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity. May cause elevated test results when measuring urinary normetanephrine; consider other alternative assay.

    Delzicol Adverse Reactions

    Adverse Reactions

    Eructation, abdominal pain, constipation, dizziness, rhinitis, back pain, rash, dyspepsia, flu syndrome; acute intolerance syndrome, hypersensitivity reactions, severe cutaneous adverse reactions (eg, SJS, TEN, DRESS, AGEP). Pediatrics: also, nasopharyngitis, headache, sinusitis, cough, diarrhea, fatigue, pyrexia, increased lipase.

    Delzicol Clinical Trials

    See Literature

    Delzicol Note

    Not Applicable

    Delzicol Patient Counseling

    See Literature

    • Latest News Your top articles for Wednesday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More